AVITA Medical Reports First Quarter Fiscal 2020 Financial Results and Company Update

Link to Full Article • U.S. RECELL® System product sales of A$4.6M for fiscal first quarter, 60% growth quarter-over-quarter • Over half of all U.S. burn centers and surgeons trained on RECELL System Valencia, Calif., USA, and Melbourne, Australia, 31 October 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a […]

ARECOR AND JDRF SIGN A JOINT RESEARCH, DEVELOPMENT AND COMMERCIALISATION AGREEMENT TO DEVELOP A CO-FORMULATION INSULIN FOR THE TREATMENT OF DIABETES

Link to Full Article Cambridge, UK., 22 October 2019: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a Research, Development and Commercialisation agreement with JDRF, the leading global organization funding type 1 diabetes (T1D) research. Under this collaboration, Arecor and JDRF will […]

Armata Pharmaceuticals Announces Receipt of $1.3 million R&D Tax Incentive

Link to Full Article MARINA DEL REY, Calif., Oct. 21, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has received a Research and Development (R&D) Tax Incentive cash rebate of USD $1.3 million from the Australian Tax Office based on Armata’s […]

Positive results published from an independent (US National Institute of Health) XF-73 phase 1 clinical trial in a peer reviewed journal

Link to Full Article The publication in the Journal of Global Antimicrobial Resistance concluded that application of a nasal gel formulation of XF-73 in healthy volunteers was safe, well tolerated and generated minimal side effects Treatment with XF-73 was also associated with a rapid reduction in nasal Staphylococcus aureus in all subjects; nasal carriage of […]

DOSING COMPLETE IN PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN PRODUCT CANDIDATE AT247 FOR DIABETES

Link to Full Article HEADLINE DATA READOUT EXPECTED Q4 2019 Cambridge, UK.,4 October 2019: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces completion of dosing and all patient visits in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247. Arecor’s AT247 […]